How much does Kisqali (Ribociclib Tablets) Cost& price without insurance in China?
Kisqali® is the commercial brand name of Ribociclib Tablets, an orally active CDK4/6 inhibitor developed by Novartis. It selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma (Rb) protein to arrest the cell cycle in G1 phase, thereby suppressing tumor cell proliferation.
Main Indications
Combination therapy with an aromatase inhibitor as initial endocrine-based treatment for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Combination therapy with fulvestrant for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy or following disease progression on prior endocrine therapy.
Common Side Effects
Common mild adverse reactions: Neutropenia, leukopenia, fatigue, nausea, diarrhea, and alopecia.
Laboratory abnormalities: Elevated liver enzymes, prolonged QT interval, and decreased lymphocyte count.
Severe but uncommon risks: Severe neutropenia with infection, hepatotoxicity, interstitial lung disease/pneumonitis, and QT prolongation leading to arrhythmias.
Approval Status in China
Kisqali® (Ribociclib Tablets, 200mg) was officially approved for marketing in China in 2023. It is currently a prescription anti-tumor drug included in China’s Category B medical insurance.
Buy Kisqali (Ribociclib Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
